Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses

Kai M Hildner1, Peter Schirmacher, Imke Atreya

  • 1Laboratory of Immunology, I Medical Clinic, University of Mainz, Langenbeckstrasse 1, Mainz, Germany. Kai.Hildner@gmx.net

Insights

Signal transducer and activator of transcription 4 (STAT4) plays a key role in rheumatoid arthritis pathogenesis. Inhibiting STAT4 reduces arthritis severity, suggesting it as a potential therapeutic target for chronic arthritis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) pathogenesis involves Th1 cytokines.
  • The role of Signal transducer and activator of transcription 4 (STAT4) in RA is not well understood.
  • STAT4 mediates signals for key proinflammatory cytokines like IL-12, IL-15, and IL-23.

Purpose of the Study:

  • To investigate the functional role of STAT4 in murine collagen-induced arthritis (CIA).
  • To assess the therapeutic potential of targeting STAT4 in arthritis.

Main Methods:

  • Utilized STAT4-deficient mice to study arthritis development.
  • Analyzed STAT4 expression in CD4(+) T cells and CD11b(+) APCs during CIA.
  • Administered an antisense phosphorothioate oligonucleotide targeting STAT4.

Main Results:

  • STAT4-deficient mice exhibited significantly reduced arthritis severity compared to wild-type controls.
  • T cells from STAT4-deficient mice produced lower levels of IL-6, TNF, and IL-17.
  • STAT4 targeting suppressed disease signs, even when initiated during disease onset.

Conclusions:

  • STAT4 is a key regulator in the pathogenesis and manifestation of murine CIA.
  • Targeting STAT4 represents a novel therapeutic strategy for chronic arthritis.